HC Wainwright Reaffirms “Buy” Rating for Enanta Pharmaceuticals (NASDAQ:ENTA)

Enanta Pharmaceuticals (NASDAQ:ENTA)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a report released on Tuesday,Benzinga reports. They presently have a $20.00 price target on the biotechnology company’s stock. HC Wainwright’s target price would indicate a potential upside of 44.61% from the stock’s previous close.

Other equities analysts have also recently issued research reports about the company. JPMorgan Chase & Co. assumed coverage on Enanta Pharmaceuticals in a report on Friday, November 14th. They issued an “overweight” rating and a $17.00 price target for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research report on Wednesday, January 21st. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $20.33.

Enanta Pharmaceuticals Stock Performance

Enanta Pharmaceuticals stock opened at $13.83 on Tuesday. The firm has a market capitalization of $401.35 million, a PE ratio of -3.61 and a beta of 0.98. The business’s 50-day simple moving average is $14.11 and its 200-day simple moving average is $11.34. Enanta Pharmaceuticals has a 52 week low of $4.09 and a 52 week high of $17.15.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings data on Monday, February 9th. The biotechnology company reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.12. The company had revenue of $18.62 million during the quarter, compared to analysts’ expectations of $16.14 million. Enanta Pharmaceuticals had a negative return on equity of 93.76% and a negative net margin of 125.36%. Research analysts forecast that Enanta Pharmaceuticals will post -4.65 earnings per share for the current year.

Insider Activity at Enanta Pharmaceuticals

In other Enanta Pharmaceuticals news, CEO Jay R. Luly sold 4,743 shares of the company’s stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $14.23, for a total transaction of $67,492.89. Following the sale, the chief executive officer directly owned 858,026 shares of the company’s stock, valued at approximately $12,209,709.98. This represents a 0.55% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Tara Lynn Kieffer sold 2,106 shares of the business’s stock in a transaction that occurred on Friday, December 5th. The stock was sold at an average price of $14.23, for a total value of $29,968.38. Following the completion of the transaction, the insider directly owned 30,620 shares in the company, valued at $435,722.60. The trade was a 6.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 11,961 shares of company stock valued at $170,149 in the last ninety days. Insiders own 11.48% of the company’s stock.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ENTA. AQR Capital Management LLC lifted its position in shares of Enanta Pharmaceuticals by 674.7% during the first quarter. AQR Capital Management LLC now owns 357,109 shares of the biotechnology company’s stock worth $1,971,000 after purchasing an additional 311,010 shares in the last quarter. Millennium Management LLC lifted its holdings in Enanta Pharmaceuticals by 50.2% during the 1st quarter. Millennium Management LLC now owns 1,346,932 shares of the biotechnology company’s stock worth $7,435,000 after buying an additional 449,945 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Enanta Pharmaceuticals by 5.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 130,410 shares of the biotechnology company’s stock valued at $720,000 after buying an additional 6,549 shares during the period. CWM LLC raised its position in shares of Enanta Pharmaceuticals by 22.1% during the second quarter. CWM LLC now owns 21,464 shares of the biotechnology company’s stock worth $162,000 after acquiring an additional 3,879 shares during the last quarter. Finally, Bank of Montreal Can boosted its holdings in Enanta Pharmaceuticals by 32.8% in the second quarter. Bank of Montreal Can now owns 33,868 shares of the biotechnology company’s stock valued at $256,000 after acquiring an additional 8,365 shares during the last quarter. Institutional investors and hedge funds own 94.99% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.